Can the HPV vaccine fully protect transgender women and people with HIV?

NCT ID NCT06624839

Recruiting now ⭐️ VACCINE ⭐️ Sponsor: University of Maryland, Baltimore Source: ClinicalTrials.gov ↗

First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time

Summary

This study is testing how well the 9-valent HPV vaccine (Gardasil9) triggers an immune response in people born male who have used estrogen or androgen blockers, including those living with HIV. Participants receive three doses of the vaccine over six months, and their immune response is measured one month after the final dose. The goal is to see if the vaccine works as well in these groups as it does in others, potentially improving protection against HPV-related cancers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 9-valent human papillomavirus (HPV) vaccine (Gardasil9)
What this could lead to: If successful, this could confirm that the HPV vaccine works well in transgender women and people with HIV, potentially improving protection against HPV-related cancers in these groups.
What could go wrong: This is a phase 2 trial with a relatively small number of participants, so results may not apply to everyone. The immune response may vary, and the study does not directly measure cancer prevention.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANAL DYSPLASIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease human papilloma virus infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANAL DYSPLASIA HIV HUMAN PAPILLOMA VIRUS

Contacts and locations

Locations

RIIS Clinic at Baltimore Safe Haven
RECRUITING

Baltimore, Maryland, 21201, United States
RIIS Clinic at HIPS
NOT_YET_RECRUITING

Washington D.C., District of Columbia, 20002, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.